Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study-MedSci.cn

Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study

Besse, B; Johnson, M; Ou, SHI; Gadgeel, S; Spira, A; Lin, J; Felip, E; van der Wekken, AJ; Calles, A; de Miguel, MJ; Camidge, DR; Elamin, Y; Lopes, GDL; Liu, S; Bauman, J; Haggstrom, D; Riley, G; Pelish, HE; Zhu, VW; Drilon, A

ANNALS OF ONCOLOGY, 2022; 33 (): S68

科室
- - 订阅+
  - 更多科室
工具
服务